Drugs / CC-90002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02641002 | Mar 2016 → Jul 2018 | acute myeloid leukemia, myelodysplastic syndrome | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT02367196 | Mar 2015 → Dec 2020 | hematopoietic and lymphoid cell neoplasm | Celgene Corporation | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-90002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02641002 ↗ |
| Action | Inhibit | “high-affinity binding to CD47 and inhibition of the CD47-SIRPα interaction” PMID 34247273 ↗ Jul 2021 |
| Modality | Monoclonal antibody | “a humanized anti-CD47 antibody” PMID 34247273 ↗ Jul 2021 |
| Route | Intravenous | “CC-90002, administered by intravenous (IV) infusion” NCT02367196 ↗ |
| Target | CD47 | “high-affinity binding to CD47 and inhibition of the CD47-SIRPα interaction” PMID 34247273 ↗ Jul 2021 |